Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Foreign, Commonwealth & Development Office:
To ask the Deputy Foreign Secretary, if he will publish the (a) minutes, (b) attendee lists, (c) expenses, (d) gifts exchanged and (e) other relevant details of the Secretary of State for Foreign, Commonwealth and Development Affairs' meeting with President Donald Trump on 8 April 2024.
Answered by David Rutley - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
Relevant transparency data relating to the Secretary of State's recent visit to the USA will be published on Gov.uk in line with the usual reporting requirements.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, if he will have discussions with the Association of British Insurers on reducing insurance premiums for households.
Answered by Bim Afolami - Economic Secretary (HM Treasury)
Treasury Ministers and officials have regular meetings with a wide variety of organisations in the public and private sectors on an ongoing basis.
Insurers make decisions about the terms on which they will offer cover following an assessment of the relevant risks. The Government does not intend to intervene in these commercial decisions as this could damage competition in the market.
However, the Government is determined that insurers should treat customers fairly. The Financial Conduct Authority requires firms to ensure their products offer fair value (i.e. if the price a consumer pays for a product or service is reasonable compared to the overall benefits they can expect to receive). The FCA has been clear that it will be monitoring firms to ensure they are providing products that are fair value, and, where necessary, it will take action.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to bring waiting times for mental health patients in-line with waiting times for physical health patients.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
We remain committed to achieving parity between mental and physical health services, as outlined in the parity of esteem definition set out in a letter to the Public Accounts Committee in February 2024.
Given funding is important for reaching parity of esteem, we are making good progress with investment in National Health Service mental health services. Between 2018/19 and 2023/24, NHS spending on mental health has increased by £4.7 billion in cash terms, as compared to the target of £3.4 billion in cash terms set out at the time of the Long-Term Plan. For 2024/25, mental health spend is forecast to continue to grow, and will make up 9.01% of all recurrent NHS spending.
In February 2022, NHS England published the outcomes of its consultation on the potential to introduce five new access and waiting time standards for mental health services, as part of its clinically led review of NHS Access Standards. These are: for an urgent referral to a community based mental health crisis service, a patient should be seen within 24 hours of referral, across all ages; for a very urgent referral to a community based mental health crisis service, a patient should be seen within four hours of referral, for all age groups; patients referred from accident and emergency should be seen face to face within one hour by a mental health liaison or children and young people’s equivalent service; children, young people and their families and carers presenting to community-based mental health services, should start to receive care within four weeks of referral; and adults and older adults presenting to community-based mental health services should start to receive help within four weeks of referral.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department for Transport:
To ask the Secretary of State for Transport, what assessment his Department has made of trends in the level of car insurance premiums in the last 12 months.
Answered by Guy Opperman - Parliamentary Under-Secretary (Department for Transport)
My Department has not made an assessment of the rising cost of motor insurance premiums over the past year. However, officials regularly liaise with representatives of the motor insurance industry on a variety of issues such as the cost of insurance. I will also soon meet with the Economic Secretary to the Treasury, and industry, to discuss this matter further.
The Government is determined that insurers should treat customers fairly and firms are required to do so under the Financial Conduct Authority rules. It is the responsibility of individual motor insurers to set their premiums and the terms and conditions of their policies, and the Government does not intervene in or seek to control the market.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department for Transport:
To ask the Secretary of State for Transport, whether he has had recent discussions with the Financial Conduct Authority on the regulation of car insurance premiums.
Answered by Guy Opperman - Parliamentary Under-Secretary (Department for Transport)
The Financial Conduct Authority does not regulate car insurance premiums. However, the Government is determined that insurers should treat customers fairly and firms are required to do so under the FCA rules.
Department for Transport officials regularly liaise with representatives of the motor insurance industry on a variety of issues such as the cost of insurance. It is the responsibility of individual motor insurers to set their premiums and the terms and conditions of their policies, and the Government does not intervene in or seek to control the market.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the availability of NHS provision for the diagnosis of ADHD in (a) Oxfordshire and (b) England.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including access to attention deficit hyperactivity disorder (ADHD) assessment and treatment, in line with relevant National Institute for Health and Care Excellence (NICE) guidance. The NICE guideline on ADHD does not recommend a maximum waiting time from referral for an assessment of ADHD to the point of assessment or diagnosis. The Department has not made a specific assessment of the availability of National Health Service provision for the diagnosis of, or treatment of, ADHD in Oxfordshire.
In respect of the adequacy of ADHD service provision nationally, in December 2023, NHS England initiated a rapid piece of work to consider ADHD service provision within the NHS. The initial phase of work identified challenges, including with current service models and the ability to keep pace with demand. Following this initial review, NHS England is establishing a new ADHD taskforce alongside the Government, to look at ADHD service provision and its impact on patient experience. The new taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to better understand the challenges affecting people with ADHD, and to help provide a joined up approach in response to concerns around rising demand.
Alongside the work of the taskforce, NHS England has announced that it will continue to work with stakeholders to develop a national ADHD data improvement plan, carry out more detailed work to understand the provider and commissioning landscape, and capture examples from local health systems which are trialling innovative ways of delivering ADHD services, to ensure best practice is captured and shared across the system.
In respect of the availability of NHS provision for the treatment of ADHD nationally, the Department is aware of, and taking action to address, disruptions to the supply of medicine used for the management of ADHD. Disruptions to the supply of medicines have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. Nationally, the Department has been working hard with industry to help resolve those issues as quickly as possible. As a result of our ongoing activity, some issues have been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, including methylphenidate and guanfacine. The latest information we have received from manufacturers is that these should largely be resolved by May 2024 and October 2024, respectively.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the availability of NHS provision for the treatment of ADHD in (a) Oxfordshire and (b) England.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including access to attention deficit hyperactivity disorder (ADHD) assessment and treatment, in line with relevant National Institute for Health and Care Excellence (NICE) guidance. The NICE guideline on ADHD does not recommend a maximum waiting time from referral for an assessment of ADHD to the point of assessment or diagnosis. The Department has not made a specific assessment of the availability of National Health Service provision for the diagnosis of, or treatment of, ADHD in Oxfordshire.
In respect of the adequacy of ADHD service provision nationally, in December 2023, NHS England initiated a rapid piece of work to consider ADHD service provision within the NHS. The initial phase of work identified challenges, including with current service models and the ability to keep pace with demand. Following this initial review, NHS England is establishing a new ADHD taskforce alongside the Government, to look at ADHD service provision and its impact on patient experience. The new taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to better understand the challenges affecting people with ADHD, and to help provide a joined up approach in response to concerns around rising demand.
Alongside the work of the taskforce, NHS England has announced that it will continue to work with stakeholders to develop a national ADHD data improvement plan, carry out more detailed work to understand the provider and commissioning landscape, and capture examples from local health systems which are trialling innovative ways of delivering ADHD services, to ensure best practice is captured and shared across the system.
In respect of the availability of NHS provision for the treatment of ADHD nationally, the Department is aware of, and taking action to address, disruptions to the supply of medicine used for the management of ADHD. Disruptions to the supply of medicines have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. Nationally, the Department has been working hard with industry to help resolve those issues as quickly as possible. As a result of our ongoing activity, some issues have been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, including methylphenidate and guanfacine. The latest information we have received from manufacturers is that these should largely be resolved by May 2024 and October 2024, respectively.